PTAB Says Rituxan Patent Challenged By Pfizer Is Obvious
The Patent Trial and Appeal Board on Wednesday handed a win to Pfizer Inc. in its challenge of a Biogen Inc. patent covering the cancer treatment Rituxan, with the board invalidating...To view the full article, register now.
Already a subscriber? Click here to view full article